GIP
Glucose-dependent insulinotropic polypeptide
Written by Aaron CuhaReviewed Sep 2026
Also known as: Glucose-dependent insulinotropic polypeptide, Gastric inhibitory polypeptide, Gastric inhibitory peptide
One of your two incretin hormones, and the parent ligand of every dual and triple agonist on this site. Both blocking it and activating it produce weight loss in humans, which nobody has resolved.
Overview
GIP is one of the two mammalian incretins. It is released by K cells in the upper small intestine when you eat and it amplifies the insulin your pancreas puts out in response to glucose. If you have read anything about tirzepatide, retatrutide or the dual and triple agonists, GIP is the G in those names, and this page exists because you cannot judge a drug that targets a receptor without knowing what normally binds it.
The interesting thing about GIP is not the insulin. It is that the field cannot agree which direction to push it. Tirzepatide activates the GIP receptor and produces large weight loss. Maridebart cafraglutide blocks the GIP receptor and also produces weight loss. Both results come from randomised human trials. This page reports that paradox rather than resolving it, because nobody has resolved it.
Mechanism of action
Binds GIPR, a class B1 secretin-family G protein-coupled receptor that is canonically Gs-coupled and raises cAMP. In the pancreatic beta cell that potentiates glucose-stimulated insulin secretion, which is glucose-dependent, so GIP does not drive insulin release when glucose is normal. GIPR is also expressed in adipose tissue, bone and the central nervous system, and the non-pancreatic actions are where most of the recent human work sits. GIP is inactivated by dipeptidyl peptidase-4, which is the same enzyme the DPP-4 inhibitor drugs block.
Human evidence
Extensive physiology, no therapeutics. GIP has been infused into people for decades to measure what it does, so the mechanistic human record is genuinely deep. No randomised trial has ever tested native GIP as a treatment for anything.
- Insulinotropic action is well characterised, glucose-dependent, and markedly blunted in type 2 diabetes.
- Repeated exposure does not blunt the response. A study across people with type 2 diabetes, their first-degree relatives and healthy controls found no tachyphylaxis, contradicting a claim that circulates widely.
- Bone resorption is acutely suppressed by GIP, shown across at least five randomised studies, and blocking the receptor blunts it. This is the most replicated non-glycaemic effect.
- GIP acts on human subcutaneous adipose tissue, promoting fatty acid re-esterification and recruiting capillaries to increase blood flow. The effect is blunted in obesity and partly restored by weight loss.
- Randomised human studies show GIP is involved in postprandial regulation of splanchnic blood flow.
- GIP receptor antagonism eliminated paradoxical growth hormone secretion in some patients with acromegaly. Note the qualifier, which is the authors' own.
What this does not tell you: Every human GIP study here is an acute or short infusion in a small group, typically ten to thirty people, measuring physiology rather than outcomes. Nothing shows that giving GIP changes bodyweight, long-term glucose control, fracture rate or any clinical endpoint. The bone findings are biomarker findings, specifically CTX suppression, not fracture findings. GIP's relevance to obesity is established through drugs that hit its receptor, not through the hormone.
Reading the research record
The honest headline on GIP is a contradiction that the field has not settled. Mouse work in 2002 showed that knocking out the GIP receptor protected against diet-induced obesity, which implied antagonism was the therapeutic direction. Two decades later tirzepatide, which agonises that same receptor, became one of the most effective weight loss drugs ever approved. Then maridebart cafraglutide, which antagonises it, produced weight loss in a randomised phase 2 trial.
Both directions work in humans. Proposed explanations exist, including receptor desensitisation under sustained agonism producing a functional antagonism, and differing central versus peripheral effects, but none is established. Competitor pages on the dual agonists routinely flatten this into a confident story about GIP amplifying GLP-1. That story may be right. It is not settled, and a reader deciding what to take deserves to know that the mechanism of the drug they are considering is genuinely disputed.
The evidence, charted
Fig. 1 · evidence composition
6of 7 citations (86%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2002 to 2025, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2018
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
The first-in-human characterisation of the molecule that became tirzepatide. This is the paper that connects GIP receptor agonism to the drug most readers of this page came here from.
Molecular Metabolism - Human2025
Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial
The other half of the paradox. Maridebart cafraglutide pairs GLP-1 receptor agonism with a GIP receptor ANTAGONIST antibody, and it produced weight loss in a randomised phase 2 trial. Blocking the receptor tirzepatide activates also works.
New England Journal of Medicine - Human2018
GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study
Ten healthy men, four-period crossover under hyperglycaemic clamp. A naturally occurring truncated fragment of GIP blocks its own receptor in people, which is the tool that made human GIP antagonism studies possible at all.
Diabetologia - Human2018
Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia
Randomised. GIP acutely suppresses bone resorption, and does so independently of insulin and blood glucose. This is the best-replicated non-glycaemic human effect of GIP.
Journal of Clinical Endocrinology and Metabolism - Human2020
GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2
Randomised. Blocking the receptor blunts the bone effect, which is the pharmacological proof that the bone finding is GIPR-mediated rather than incidental.
Bone - Human2020
No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects
A negative result against a widely repeated claim. GIP responsiveness does not appear to degrade on repeated exposure, in any of the three groups tested.
Peptides - Animal2002
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Mouse. GIP receptor knockout mice are protected against diet-induced obesity. This is the origin of the entire agonism-versus-antagonism question and it is a mouse result, which is why the question took two decades of human work to even begin testing.
Nature Medicine
Frequently asked questions
Is GIP something I can take?
No. It is a hormone your gut already makes, and it is not an approved drug anywhere. It is used as a research infusion to study physiology. The drugs on this site act at its receptor; they are not GIP.
Why does tirzepatide activate GIP receptors if blocking them also causes weight loss?
Nobody knows, and that is the most interesting thing about this hormone. Both directions have produced weight loss in randomised human trials. Proposed explanations include desensitisation under sustained activation producing an effect like blockade, and different actions in the brain versus the body. None is established.
What does GIP do besides insulin?
The best-replicated non-glycaemic effect is on bone: GIP acutely suppresses bone resorption, shown in several randomised studies, and blocking the receptor blunts it. It also acts on adipose tissue, promoting fat storage and increasing blood flow there, and that adipose effect is blunted in obesity.
Is the GIP bone finding a reason to expect fewer fractures on a GIP drug?
No. Those studies measured a bone resorption marker over hours, not fractures over years. A marker moving in a favourable direction is a reason to run the longer study, not a substitute for it.